Kim Jones retweetledi

PhaseII trial of cabozantinib in refractory germ-cell tumors. Nice to see activity and clinical benefit in very refractory/heavily pretreated population. Important to continue drug development in this disease! @JenniferKingMD @IUCancerCenter @TestesCancer @TestesCancer



English



















